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Abstract 
Although treatment for heart failure induced by cancer therapy has improved in recent years, the 
prevalence of cardiomyopathy due to antineoplastic therapy remains significant worldwide. In addition to 
traditional mediators of myocardial damage, such as reactive oxygen species, new pathways and target 
cells should be considered responsible for the impairment of cardiac function during anticancer treatment. 
Accordingly, there is a need to develop novel therapeutic strategies to protect the heart from 
pharmacologic injury, and improve clinical outcomes in cancer patients. The development of novel 
protective therapies requires testing putative therapeutic strategies in appropriate animal models of 
chemotherapyinduced cardiomyopathy. This Position Paper of the Working Group on Drug Cardiotoxicity 
and Cardioprotection of the Italian Society of Cardiology aims to: (1) define the distinctive etiopatogenetic 
features of cardiac toxicity induced by cancer therapy in humans, which include new aspects of 
mitochondrial function and oxidative stress, neuregulin-1 modulation through the ErbB receptor family, 
angiogenesis inhibition, and cardiac stem cell depletion and/or dysfunction; (2) review the new, more 
promising therapeutic strategies for cardioprotection, aimed to increase the survival of patients with severe 
antineoplastic-induced cardiotoxicity; (3) recommend the distinctive pathological features of cardiotoxicity 
induced by cancer therapy in humans that should be present in animal models used to identify or to test 
new cardioprotective therapies.  
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Introduction 
Congestive heart failure (CHF) is the leading cause of disability in long-term survivors of cancer. The 
pathological consequences of CHF arise from the detrimental effects of antineoplastic drugs resulting in 
cardiomyocyte death, heart failure, arrhythmias, and death. The major concern is about cardiotoxicity 
associated with anthracyclines. Retrospective analyses from clinical trials in adults showed that the risk of 
CHF due to anthracyclines therapy is cumulative, dose related, and rises from *5  % at doxorubicin dose of 
400 mg/m2  to 16  % at doses exceeding 500 mg/m2  [1]. This risk may be increased if we consider the 
cumulative effects of the drug over time. Using the Surveillance, Epidemiology, and End Results Medicare 
(SEER) database, it was found a cumulative 38 % rate of CHF over 10 years in women aged 66  years and 
older who had received adjuvant anthracyclines [2]. This can be compared with a rate of 33  % in women 
treated with regimens not containing an anthracycline and 29  % in those with no adjuvant chemotherapy 
[2]. There is also concern about cardiotoxicity associated with the anti-HER- 2  monoclonal antibody 
trastuzumab. However, while anthracycline cardiotoxicity is largely irreversible, patients experiencing CHF 
when taking trastuzumab often recover [3]. Novel therapeutic interventions, which are capable of limiting 
cardiomyocyte death, are required to improve clinical outcomes in cancer patients. A variety of 
cardioprotective interventions has been investigated over the years in several small clinical trials, despite 
disappointing results. A through understanding of basic mechanisms of cancer therapy-induced cardiac 
toxicity is crucial for identifying new treatment strategies and novel targets for cardioprotection. Research 
to identify novel targets and cardioprotective therapies for cancer-induced cardiac injury usually requires 
preclinical testing in appropriate animal models. Although numerous animal models are available for use, 
there are inadequate standards for what clinical features of the cardiomyopathy due to antineoplastic 
therapy should be present in these models, and the presence or absence of the cancer-induced 
cardiotoxicity phenotype is often not documented. The aim of this Position Paper is first to define the 
distinctive etiopatogenetic features of cardiac toxicity induced by cancer therapy in humans; then to review 
the novel promising therapeutic strategies for cardioprotection; finally to recommend those distinctive 
pathological features of cardiac toxicity induced by cancer therapy in humans that should be present in an 
animal model being used to identify or to test novel cardioprotective therapies. 
 
Novel mechanisms of cardiotoxicity  
Mitochondrial dysfunction and oxidative stress  
The antineoplastic activities of anthracyclines are due to several mechanisms of action, including the 
formation of topoisomerase II complex that impairs DNA replication as well as the induction of apoptotic 
cascades [4] and oxidative stress, which can occur via both enzymatic and nonenzymatic pathways [5]. 
Oxidative stress, due to generation of reactive oxygen species (ROS), is also the most widely accepted 
mechanism of anthracycline-induced cardiac toxicity [6, 7]. Anthracyclines undergo redox cycling with 
generation of ROS such as superoxide anion (O2-) and hydrogen peroxide (H2O2), with consequent oxidative 
stress, energy depletion in cardiomyocytes, impaired mitochondrial function, cellular membrane damage, 
apoptosis, and cytotoxicity [8]. Recent data suggest that the cardiotoxicity induced by anthracyclines also 
occurs via the isozyme Top2b in cardiomyocytes. Anthracyclines are intercalating agent, capable of 
inserting between DNA base pairs and Top2b, leading to the formation of ternary Top2b–doxorubicin–DNA 
complex in the cardiomyocytes. This complex inhibits the re-ligation of the broken DNA strands, leading to 
DNA double-strand breaks and cell death [9]. In fact, after exposure to doxorubicin of cardiomyocytes 
harvested from conditional, cardiomyocytespecific Top2b knockout mouse, results marked reduction in 
DNA double-strand breaks, apoptotic nuclei, abnormalities in the p53 tumor suppressor gene, b-adrenergic 
signaling, and extrinsic and intrinsic apoptotic pathways as compared to wild-type mice [9]. With prolonged 
doxorubicin exposure, wild-type cardiomyocytes (but not Top2b KO cardiomyocytes) showed worse 
alterations in the expression of genes that regulate mitochondrial function, biogenesis, and oxidative 
phosphorylation [9], leading eventually to mitochondrial dysfunction and ROS generation [10]. Indeed, 
doxorubicin cardiotoxicity is blunted in mice knockout for the gene encoding the cardiac topoisomerase 2b 
[10]. In mitochondria, anthracyclines may inhibit the electron transport chain process [11]. They have a 
high affinity for cardiolipin, which is involved in various phases of mitochondrial apoptotic process [11]. 
Nevertheless, ROS-dependent cardiolipin peroxidation may play a crucial role in the release of cytochrome 
C, which can also favor cardiolipin peroxidation, in a vicious cycle that ultimately leads to apoptosis [12]. 
Sildenafil, a phosphodiesterase- 5 inhibitor which has been proven to limit ischemia/reperfusion myocardial 
injury, can also protect against doxorubicin-induced myocardial toxicity [13, 14]. Cardioprotection by 
sildenafil against doxorubicin-induced myocardial injury was abolished by the nitric oxide synthase inhibitor 
L-NAME, which has been shown to inhibit mitochondrial ATP-sensitive potassium channels [15]. These 
results indicate that sildenafil’s effect on nitric oxide pathway and on the opening of mitochondrial ATP-
sensitive potassium channels may limit doxorubicin-induced cardiotoxic effects. 
Inhibition of ErbB2 
ErbB2 is a member of the EGFR family. It is expressed in cardiomyocytes [16] and overexpressed in about 
30 % of breast cancers [17]. ErbB2  interacts with the other ErbBs, triggering signaling cascade that 
promotes tumor growth and survival [18]. The humanized anti-ErbB2  monoclonal antibody trastuzumab 
(herceptin) is effective in treating ErbB2? cancers, but unfortunately causes cardiotoxicity [19, 20], arising 
from impairment of contractility rather than loss of myocytes [21]. Neuregulin-1  (NRG1) is a small peptide 
and ligand receptor released from microvascular endothelial cells. In cardiomyocytes, NRG-1  acts via 
ErbB4/ErbB4  homodimers and ErbB4/ErbB2  heterodimers to stimulate protective pathways [22]. The 
ErbB2  pathway is needed for cell survival and function (PI3/AKT and MEK/ERK pathways) and is activated 
when the myocardium faces adverse hemodynamics or other stress, such as anthracyclines [23]. Activation 
of NRG1/ErbB pathway induces cell-cycle reentry of differentiated cardiomyocytes, with consequent 
cardiomyocyte proliferation and promotion of cardiac repair [24]. Trastuzumab cardiotoxicity is due to its 
binding to the extracellular domain of ErbB2  on cardiomyocytes, blocking myocardial ErbB2–ErbB4  cell-
protective, growth promoting pathway [25–28]. Consistently, ErbB2  cardiac KO mice showed dilated 
cardiomyopathy, with enhanced myocytes death after anthracyclines [29]. Upon trastuzumab withdrawal, 
normal ErbB2  signaling is restored, and the decreased EF can return to normal, opposite to anthracyclines 
[30]. This is consistent with the enhanced cardiotoxicity occurring upon association of trastuzumab with 
anthracyclines: Trastuzumab amplifies the damage caused by anthracyclines. Once blocked the repair 
mechanisms because of ErbB2  blockade, the oxidative damage induced by anthracyclines proceeds 
without control [21]. Indeed, experimental studies have shown that neuregulin-1  modulates doxorubicin 
damage in rat cardiomyocytes [4, 16, 27, 31]. 
Inhibition of angiogenesis 
Antiangiogenic drugs inhibit VEGF signaling and are associated with cardiovascular side effects [32, 33] such 
as arrhythmias, myocardial ischemia, and infarction, but in most cases hypertension and 
thromboembolism, LV dysfunction, and HF. Indeed, like cancer, the heart depends on adequate perfusion 
for its normal function [25, 28, 34–38], both relying on similar HIF-1  and VEGF pathways. In particular, the 
heart is sensitive to antiangiogenic therapy especially in the setting of stress such as hypertensionrelated 
pressure overload. Bevacizumab (avastin) is an antibody which binds circulating VEGF-A, currently 
approved for the treatment of advanced carcinoma of the lung, breast, colon, rectum [39]. It has been 
reported to induce left ventricle dysfunction (3  % after prior chemotherapy; 1  % with bevacizumab alone) 
[40]. Instead, sunitinib (sutent) and sorafenib (nevaxar) are small molecule tyrosine kinase inhibitor (TKI) 
with strong antiangiogenic activity, used in metastatic renal cancer and in imatinib-resistant 
gastrointestinal stromal tumors (GIST) [41, 42]. Interestingly, sunitinib and sorafenib are not very selective 
[34], since they target also other kinases, besides VEGF receptors. Sorafenib inhibits at least 15  kinases, 
including the PDGF receptor as well as VEGFRs and Raf-1/B-Raf, including KIT and FLT3  [25, 34, 35]. 
Sunitinib is reported to be more cardiotoxic, causing a decrease in left ventricle ejection fraction (LVEF) in 
up to 28 % of patients [43–46], since it inhibits more than 30 other kinases, including c-kit, plateletderived 
growth factor receptor (PDGFR) alpha and beta, rearranged during transfection (RET), FMS-related tyrosine 
kinase 3  (FLT3), and colony-stimulating factor 1  receptor (CSF1R) [25, 34, 35, 47]. Seminal studies [48–52] 
have proven the importance of such pathways in cardiovascular homeostasis. The higher incidence of 
sunitinib cardiotoxicity is also explained by inhibition of off-target kinases, such as ribosomal S6  kinase 
(RSK), with consequent activation of the intrinsic apoptotic pathway, and 50 AMP-activated protein kinase 
(AMPK, important for the response to energy stress), with worsening of ATP depletion [25, 53]. Therefore, 
LV dysfunction would occur due to myocyte dysfunction. 
Stem cells 
The adult heart has been recently shown to contain specific cardiac stem cells (CSCs) and cardiac progenitor 
cells (CPCs) that are cycling and can provide cell replacement for dying cardiomyocytes [54, 55]. These cell 
populations may be sensitive to the interference of anthracyclines on DNA replicative machinery, resulting 
in the inhibition of CSC/CPC proliferation. This phenomenon may be operative in anthracycline-induced 
cardiomyopathy, so that repeated administration of the drug may affect the population of CSCs/CPCs that 
are activated in an attempt to repair the damaged myocardium. In fact, recent data have shown that 
exposure to doxorubicin over a period of 6 weeks led to an almost complete depletion of the CSC/ CPC pool 
within the myocardium, due to inhibition of CSC/CPC division in combination with the accumulation of 
oxidative DNA damage, growth arrest, cellular senescence, and apoptosis. This results in negative 
interference with the physiological turnover of cardiomyocytes and their regeneration in the presence of 
diffuse cell death [56]. Moreover, impaired high-energy phosphate metabolism and increased production 
of ROS might also affect negatively the function and survival of all cardiac compartments including 
CSCs/CPCs. All these negative effects can result in an impairment of myocyte replacement. Inhibition of the 
stem cell growth factor receptor c-kit is an additional mechanism by which stem cells may contribute to 
cardiotoxicity. Both sunitinib and sorafenib inhibit c-kit, which is expressed by precursors for hematopoietic 
stem cells, endothelial progenitor cells, and CPCs and is involved in the stem cell mobilization into the injury 
area [25]. Reduced c-kit kinase activity is proposed as additional mechanism of cardiotoxicity due to TK 
receptor inhibitors since it impairs the cardiac repair after injury [57]. 
Novel cardioprotective strategies 
Antioxidant therapies 
A variety of antioxidants has been studied for cardioprotection against anthracycline-induced cardiotoxicity 
in animal models and small human clinical trials, including probucol, vitamin E, and N-acetylcysteine, 
without benefits [58] (Table 1). The only evidence for prevention of anthracycline- induced cardiotoxicity 
has been shown for dexrazoxane, beta-blocker, angiotensin-converting-enzyme (ACE) inhibitors, and 
statins. Dexrazoxane is a pro-drug analog of the ethylenediaminetetracetic acid (EDTA), which acts as iron 
chelating agent, thereby preventing the formation of anthracycline–iron complexes and subsequent ROS 
formation. In addition to the antioxidative effects, dexrazoxane directly interferes with the formation of 
anthracycline-induced Top2a– and Top2b–DNA complexes, thereby reducing DNA damage [9]. A recent 
meta-analysis showed decreased risk of HF in cancer patients treated with dexrazoxane; however, the 
overall survival of these patients did not change [59]. Statins have been shown to exert cardioprotective 
effects against anthracycline-induced cardiotoxicity both in preclinical studies and in small human studies 
or retrospective observational studies. In vitro studies showed that lovastatin reduced doxorubicin-induced 
cardiomyocyte death and Top2b-mediated DNA damage [60]. Murine models of doxorubicin-induced 
cardiotoxicity showed attenuation of troponin I elevation and decreased cardiac fibrosis and left ventricular 
dysfunction after lovastatin cotreatment [61]. Retrospective observational studies showed reduction in 
hospitalization for HF in breast cancer patients co-treated with anthracyclines and statins [62]. In a small 
study of 40 patients treated with anthracyclines and randomized into statin group or control group, 
atorvastatin showed significant improvement of left ventricular ejection fraction as compared to control 
group [63]. In animal models of anthracycline-induced cardiotoxicity, aerobic exercise prior to and during 
anthracycline administration has been shown to exert cardioprotective effects in terms of decreased 
activation of pro-apoptotic cascade and increased proliferation of cardiomyocytes, essentially via reduction 
in ROS formation [64]. While exercise did not show beneficial effects in cancer patients treated with 
trastuzumab, there are small human studies showing reduction in all-cause mortality in 
anthracyclinetreated patients [65]. Further evidence will come from several registered large clinical trials 
evaluating the effect of exercise on anthracycline-induced cardiotoxicity (http:// www.clinicaltrials.gov/). 
Nutraceuticals, mostly phytochemicals derived from dietary or medicinal plants, such as soya bean, garlic, 
ginger, tea as well as propolis, honey, may have beneficial effects, mostly related to reduction in 
chemotherapy collateral effects, such as already suggested by epidemiologic studies [66]. Their ability to 
reduce cancer incidence in these studies is likely related to apoptosis and antioxidant properties. However, 
concerns exist about their real benefit in cancer patients which led to advise patients not to take them [67]. 
The concerns concentrate mainly on the interaction between the nutritional supplements and the 
chemotherapeutic agent used and its metabolization [68]. This is due to the fact that very often are not 
known the pharmacodynamics and pharmacokinetics of these substances in depth. Therefore, proper 
identification of molecular targets of nutraceuticals in vitro and preclinical studies is of primary importance 
to avoid offtarget effects and maximize their successful use in cancer patients.  
Angiotensin-converting-enzyme inhibitors 
Disruptions of the renin–angiotensin–aldosterone system (RAAS) are important in determining myocardial 
dysfunction induced by antineoplastic chemotherapies. Several small studies involving angiotensin II 
blockers administered during chemotherapies have investigated whether RAAS modulation could reduce 
antineoplastic-induced cardiomyopathy. For instance, ACE inhibitors have been shown to exert 
cardioprotective effects against anthracycline- induced cardiotoxicity both in animal and in small human 
studies [69], essentially via reduction in ROS formation [70]. Captopril and enalapril have been seen to 
reduce oxidative stress, downregulating the generation of ROS and preventing doxorubicin-induced 
cardiomyopathy [71]. ACE inhibitors may also reduce interstitial fibrosis [72] and may be protective via 
modulation of PPARb/c gene expression [73]. Yet candesartan, an angiotensin II type 1 receptor antagonist, 
reversed fibrosis and apoptosis and improved myocyte diameter/body weight ratio in a model of 
daunorubicin-induced cardiomyopathy [74]. The ACE inhibitor valsartan added to the CHOP chemotherapy 
(cyclophosphamide, doxorubicin, vincristine, and prednisolone) resulted protective improving 
echocardiographic and electrocardiographic parameters [75]. Finally, ACE inhibitors have been shown to 
exert cardioprotective effects against cardiotoxicity-induced trastuzumab via downregulation of NRG-/ErbB 
pathway [76]. Currently, there are several registered large clinical trials evaluating the effect of ACE 
inhibitors on trastuzumab- and anthracycline- induced cardiotoxicity (http://www.clinicaltrials. gov/). 
Beta-Adrenergic signaling blockers 
Although beta-blockers, such as carvedilol, nebivolol, alprenolol, have been recommended in preventing 
cardiac dysfunction during anthracycline treatment [77], clinical trials investigating the specific effects of 
this class of drug in HF patients with cancer are lacking or underway. In fact, most of the evidence comes 
from retrospective studies [78–82]. Compared to placebo, carvedilol seems to attenuate theLVEF decline 
and diastolic function impairment in patients treated with anthracyclines [81]. Similarly, a reduction in LVEF 
and an increase in LV volumes and brain natriuretic peptide (BNP) levels were shown in patients with breast 
cancer treated with placebo compared to those treated with nebivolol [79]. Additionally, a prognostic role 
was shown in patients with malignant hemopathies treated with anthracyclines, receiving placebo, or 
enalapril plus carvedilol. Patients treated with placebo experienced more frequently occurrence of death 
and HF. All patients had normal baseline EF and no variation of troponin levels. Echocardiographic data 
were also confirmed by cardiac magnetic resonance [82]. In other study examining the role of metoprolol 
or enalapril or placebo, the two drugs reduced the incidence of symptomatic HF, although the difference 
did not achieve significance [83]. Moreover, there was no difference in echocardiographic parameters of LV 
function among the 3 groups [83]. Possible mechanisms of beta-blockers-induced cardioprotection include 
downregulation of catecholamine stimulation with preservation of b-arrestin signaling pathway 
transactivation of ErbB1 (epidermal growth factorreceptor) [84] and prevention of myocardial calcium 
overload resulting in enhanced lusitropy [85]. Carvedilol also exhibits antioxidative effects [86]. More 
robust trials, such as preventiOn of left Ventricular dysfunction with Enalapril and caRvedilol in patients 
submitted to intensive ChemOtherapy for the treatment of Malignant hEmopathies (OVERCOME) [82], 
PRevention of cArdiac Dysfunction during Adjuvant breast cancer therapy (PRADA) [87], and MANTICORE-
101  breast (multidisciplinary approach to novel therapies in cardiology oncology research trial) [88], 
investigating the effects of combined treatment with betablockers and ACE inhibitors on anthracycline- and 
trastuzumab- induced cardiotoxicity, are undergoing. 
Stem cell therapy 
CSCs and CPCs offer novel and promising cardioprotective strategy for cancer therapy-induced 
cardiotoxicity, mainly through paracrine effects [56, 89–94]. Several signaling pathways including Akt [92] 
andNotch [91] are advocated to mediate the cardioprotective effects of CSCs and CPCs. It has been shown 
that transplantation of syngeneic CPCs via intramyocardial injection improves heart function in preclinical 
models of doxorubicin-induced cardiomyopathy [56]. Unfortunately, there are currently no registered 
clinical trials using CSCs or CPCs in cancer patients with cardiomyopathy (http://www.clinicaltrials.gov/). To 
date, preliminary results from preclinical studies are promising, although they remain inconclusive in terms 
of long-term effects. Extreme caution must be taken in the translation of these animal studies to 
humans.Nevertheless, these studies arise some possibility that myocardial biopsies may be obtained before 
antineoplastic drugs are given to cancer patients, and autologous CSCs or CPCs can be isolated and 
expanded from these myocardial samples and injected back into the cardiomyopathic heart of neoplastic 
patient. After transplantation, these cells can contribute to cardioprotection in the course of cancer 
therapyinduced cardiac injury, primarily via paracrine effects, i.e., secretion of growth factors. Evidence is 
accumulating that these released factors direct a number of restorative processes including myocardial 
protection, neovascularization, and reduction in cardiac fibrosis [91, 92]. 
Preclinical models of chemotherapy-induced cardiotoxicity 
A variety of small and large animal models [95], as well as in vitro models [96], have been used to study the 
pathophysiology of cancer therapy-induced cardiomyopathy and pharmacological or nonpharmacological 
cardioprotective therapies. The limited translability of results from in vitro and animal models to human 
reflects the inability of any particular model to reproduce the pathophysiology of the disease in its 
complexity as in humans. Furthermore, results on toxic or therapeutic effects of antineoplastic drugs in 
various animal species are found extremely variable and not always similar to humans. Therefore, we can 
only partially compare precisely the dose and the toxic/ therapeutic effects of antineoplastic drugs 
between the animal model and the humans. Although small animals, such as murine and rat models, are 
low cost, readily available, easy to handle, results of studies evaluating cancer therapy-induced 
cardiomyopathy and its treatments in these models have offered only limited predictive clinical value. In 
rats, endovenous administration of anthracycline antibiotics causes morphologic lesions of the myocardium 
in a dose-related manner, with significant changes in the heart function in terms of intraventricular 
conduction defects and reduction in ejection fraction and mitochondria alterations in terms of inhibition of 
electron transfer, uncoupling of oxidative phosphorylation, and inhibition of calcium translocation [97]. 
However, these changes are more difficult to demonstrate than in larger animals. Large animal models, 
such as the rabbit and porcine models, have proven to be more predictive of cancer therapy-induced 
cardiomyopathy and its treatments in humans, although their predictive value is not absolute. The use of 
large mammalian models, however, is difficult to do, in part due to animal welfare restrictions and high 
costs of long-term monitoring of animals. In fact, because of chronic and delayed anthracycline 
cardiotoxicity [96], large animals require to be monitored for extended period. Even when large 
mammalian models are used, they most often do not take into consideration extreme age (i.e., children 
and very old people), co-morbidities, and comedications which a patient with cancer would most likely 
have. Taken together, lack of prediction and conflicting findings are related, in some instances, to species-
dependent sensitivity to cardiac injury—that does not necessarily reflect disease in humans—which in turn, 
is modulated by anatomical factors, metabolism, idiosyncratic toxicity reactions, immunological responses, 
as well as co-morbidities and their routine medications. Most experimental studies on cardioprotection are 
still undertaken in healthy juvenile animal models, although cancer therapy-induced cardiotoxicity in 
humans is a complex disorder that can be aggravated by or associated with cardiovascular risk factors and 
co-morbidities, including arterial hypertension, hyperlipidemia, diabetes, and aging. These risk factors 
induce fundamental alterations in cellular signaling cascades that affect the severity of antineoplastic drug-
induced cardiotoxicity and the responses to cardioprotective interventions [98]. Another important aspect 
to consider when testing the efficacy of a novel cardioprotective therapy is to ensure that the timing of the 
drug administration takes into account the clinical setting of the cancer therapy-induced cardiomyopathy. If 
early ventricular dysfunction in antineoplastic drug-treated patients is the intended clinical target, then it 
would be essential to demonstrate that the novel cardioprotective therapy can prevent early the left 
ventricular ejection fraction drop C10 % or even more sensitive parameters of left ventricular function at 
echocardiography or magnetic resonance imaging (MRI) when administered just prior or at the onset of 
anticancer treatment [99]. However, a decrease in left ventricular ejection fraction does not always predict 
early cardiac damage. In particular, markers of cardiomyocyte degeneration (such as serum levels of cardiac 
troponins) or elevated ventricular end-diastolic pressure or volume (such as serum levels of natriuretic 
peptides) or myocardial strain and strain rate as detected with Doppler echocardiography should be further 
evaluated in preclinical models [95, 96, 100]. Finally, the use of appropriate vehicle/sham control groups 
needs to be included in the study especially when pharmacological or stem cell-based therapeutic 
interventions are being considered [101, 102]. In conclusions, despite species-related or model-dependent 
differences, valuable insights into the molecular mechanisms of antineoplastic drug-induced 
cardiomyopathy can be deduced, but extrapolation from these animal findings to clinical relevance in 
humans should be made cautiously. Appropriate model application, respect and understanding of model 
limitations, and appropriate interpretation of the study results in light of model limitations should be taken 
into account. Therefore, continued development and characterization of suitable preclinical models are 
necessary in order to reproduce in animals antineoplastic drug-induced cardiomyopathy of humans and its 
treatment. 
The road ahead: toward clinical translation 
There are now a number of clinical and preclinical studies which have looked at cardioprotection by 
pharmacological agents, aerobic exercise, or advanced therapy (stem cell therapy) in various clinical 
scenarios of cancer therapy-induced cardiomyopathy. Most of the data regarding mechanisms of 
cardiotoxicity and cardioprotection have been obtained in animal models. Translatability of these results in 
the humans is always challenging; therefore, further studies are needed in order to assess the relevance of 
the pathways in human. With respect to pharmacological cardioprotection, both positive and negative 
human studies suffer from small cohort sizes, are retrospective and/or nonrandomized studies, and lack 
early clinical outcome as endpoint. Nevertheless, most, but not all, studies demonstrated improved 
functional parameters of the left ventricle, such as ejection fraction as measured by echocardiogram. 
Several ongoing multicenter trials on pharmacological cardioprotection, such as OVERCOME [82], PRADA 
[87], and/or MANTICORE- 101  breast [88] will provide more insight into the effects of combined treatment 
with beta-blockers and ACE inhibitors on anthracycline-induced cardiotoxicity or in the setting of 
trastuzumab therapy. There are novel options for cardioprotective therapies such as stem cell therapy, 
reviewed above that are underway for the investigation. Accordingly, a number of stem cell approaches for 
preservation or expansion of the cardiac progenitor cell pool have been investigated in animal models of 
anthracycline-induced cardiomyopathy. Although these alternative therapies are not ready yet for the 
phase of clinical translation, they may change the onset and development of cardiovascular damage by 
cytotoxic drugs. Pharmacological strategies as well as stem cell preparations are promising options for 
cardioprotection; however, results are still controversial and the stem cell strategies did not reach the 
clinical translation phase. With regard to human studies, the reasons for some negative results with 
betablockers and ACE inhibitors can be attributed to small patient cohorts and poorly designed clinical 
studies. With respect to stem cell-mediated cardioprotection, unfortunately human studies have not been 
designed so far that could reveal the relevance of the cardiac stem cell compartment in the 
pathophysiology of cancer therapy-induced cardiotoxicity, and the role of stem cell therapies aimed at the 
preservation or expansion of the cardiac progenitor cell pool. 
Recommendations 
In this SIC WG Position Paper, we have outlined basic mechanisms of cardiac toxicity induced by 
antineoplastic drugs and discussed promising therapeutic strategies for cardioprotection. We would like to 
make the following recommendations when assessing in preclinical models the clinical potential of a novel 
cardioprotective therapy: (1) The experimental models of cancer therapy-induced cardiotoxicity must 
include confounding factors such as comorbidities (such as age, diabetes, hypertension, dyslipidemia) and 
concomitant medication, which are known to potentially have an impact on the extend of antineoplastic 
drug-induced cardiotoxicity; (2) in the preclinical assessment, the novel cardioprotective therapy should be 
demonstrated to be effective after taking into account the effect of the above-mentioned confounding 
factors, known to potentially have an impact on cardioprotection. 
Conclusion 
Pharmacological and nonpharmacological attempts that aim to protect the heart against cardiotoxicity in 
cancer patients are encouraging, but human level data are presently not enough to support the effects of 
these interventions. Furthermore, there are several limitations of the preclinical models of cardiotoxicity 
that could hamper direct translation of new findings, including co-treatments, risk factors for 
cardiovascular disease, and other co-morbidities. In this SIC WG Position Paper, we share novel insights and 
potential targets that can be used for cardioprotection, providing the potential rationale for both existing 
and novel therapy, and noting areas where further research is needed. We also provide recommendations 
for optimizing the process of clinical translation of novel cardioprotective therapies tested in preclinical 
models of antineoplastic drug-induced cardiotoxicity. In regard to mechanisms and targets for 
cardioprotection, a central role is still played by the generation of ROS in the cardiomyocytes, which is 
considered as criticalmediator ofmyocardial damage during cancer therapy, especially anthracycline-
mediated cardiotoxicity. Additional pathways including NRG1/ErbB pathway and tyrosine kinase receptors 
should be considered as responsible for the deterioration of cardiac performance as well. Alternatively, or 
rather additionally, a novel mechanism explaining antineoplastic drug-induced cardiotoxicity is given by 
depletion and/or dysfunction of the CSC compartment, which in turn might expire a more complex 
approach to the cardioprotection. Here, cardioprotective effects can be achieved via growth factors 
secreted by CSCs/CPCs, which can therefore influence several levels of protection in the myocardium in the 
course of antineoplastic drug-induced cardiotoxicity. The translation of novel cardioprotective approaches 
into the clinical setting for cancer patients has been challenging for the above-mentioned shortcomings of 
preclinical models and for the absence of clinical trials adequately designed and sufficiently empowered. 
Therefore, large clinical studies and more complex preclinical models will be necessary to get more insight 
into the clinical applicability of the novel cardioprotective strategies. 
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